- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04794686
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
This research is being done to find out more information about a brain tumor called Embryonal Tumor with Multilayer Rosettes (ETMR) by collecting medical information from children who have this disease.
The purpose of this research study is to create and maintain a research database for patients with ETMR. The database will include information about occurrence rates, patient information, tumor tissue information, and response to treatment. This will help advance our understanding of this rare disease.
In addition, this study will include obtaining survival data and evaluating therapeutic response to expert consensus therapy, and procuring patient tumor tissue.
Study Overview
Status
Conditions
Detailed Description
All patients with ETMR are eligible for inclusion within the registry, regardless of their disease status or treatment plan. Epidemiologic, clinical, and molecular data from each patient will be obtained following enrollment. Patients will then be followed longitudinally to obtain clinical outcome data. In an effort to best achieve the registry's secondary objectives, it is preferable, but not required, for patients to be registered soon after their diagnosis, prior to the initiation of any tumor-directed therapy.
This registry protocol contains recommendations for a consensus therapy derived from the ETMR medical literature, the investigators' own experience, and clinical data from other infant brain tumor protocols. The recommended therapy can thus not be viewed as investigational, but rather as a consensus recommendation derived from available data. While not mandated, it is strongly encouraged that patients enrolled in the registry be treated according to the recommended consensus therapy, as this will facilitate the prospective evaluation of ETMR patients using a uniform treatment approach.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Derek Hanson, MD
- Phone Number: 551-996-8437
- Email: Derek.Hanson@HMHN.org
Study Contact Backup
- Name: Sherri Mayans, MSN
- Phone Number: 551-996-2283
- Email: Sherri.Mayans@HMHN.org
Study Locations
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
Contact:
- Sherri Mayans, MSN
- Phone Number: 551-996-2283
- Email: Sherri.Mayans@HMHN.org
-
Contact:
- Elana Smilow, MSN
- Phone Number: 551-996-5673
- Email: Elana.Smilow@HMHN.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of any age
- Patients must have either a histologically confirmed primary intracranial CNS Embryonal Tumor with Multilayer Rosettes (as agreed upon by central review or local pathologist OR
- Patients must have tumor tissue that possesses C19MC amplification . Central Review is not required (but is strongly recommended) if the patient's tumor does not demonstrate C19MC amplification.
- Patients may be enrolled at point following diagnosis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ETMR One Registry
Time Frame: 10 years
|
To create and maintain a comprehensive registry containing the epidemiologic, clinical, and molecular data of patients with embryonal tumor with multilayer rosettes.
|
10 years
|
Efficacy of consensus therapy on median event-free survival
Time Frame: 10 years
|
To investigate the efficacy of the consensus regimen of chemotherapy, high-dose chemotherapy with autologous stem cell rescue, and radiotherapy (as indicated) following maximal feasible surgical resection for patients with newly-diagnosed ETMR as measured by median event-free and overall survival in comparison to historical controls.
|
10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Derek Hanson, MD, Hackensack Meridian Health
Publications and helpful links
General Publications
- Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS, Kim SK, Ra YS, Fangusaro J, Korshunov A, Toledano H, Nakamura H, Hayden JT, Chan J, Lafay-Cousin L, Hu P, Fan X, Muraszko KM, Pomeroy SL, Lau CC, Ng HK, Jones C, Van Meter T, Clifford SC, Eberhart C, Gajjar A, Pfister SM, Grundy RG, Huang A. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug;13(8):838-48. doi: 10.1016/S1470-2045(12)70257-7. Epub 2012 Jun 11.
- Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DT, Remke M, Northcott P, Perry A, Picard D, Rosenblum M, Antonelli M, Aronica E, Schuller U, Hasselblatt M, Woehrer A, Zheludkova O, Kumirova E, Puget S, Taylor MD, Giangaspero F, Peter Collins V, von Deimling A, Lichter P, Huang A, Pietsch T, Pfister SM, Kool M. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014 Aug;128(2):279-89. doi: 10.1007/s00401-013-1228-0. Epub 2013 Dec 14.
- Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, Perry A, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schuller U, Hasselblatt M, Collins VP, von Deimling A, Lichter P, Huang A, Pfister SM, Kool M. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol. 2012 Dec;124(6):875-81. doi: 10.1007/s00401-012-1068-3. Epub 2012 Nov 16.
- Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 8;16(6):533-46. doi: 10.1016/j.ccr.2009.10.025. Erratum In: Cancer Cell. 2010 Apr 13;17(4):413.
- Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI; DIAGRAM Consortium; MAGIC Investigators; Altshuler D, Daley GQ. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011 Sep 30;147(1):81-94. doi: 10.1016/j.cell.2011.08.033.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro2020-0391
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Embryonal Tumor With Multilayered Rosettes
-
OHSU Knight Cancer InstituteNational Institute of Neurological Disorders and Stroke (NINDS); Oregon Health...Active, not recruitingMedulloblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Medulloblastoma | Germ Cell Tumor | Primitive Neuroectodermal Tumor | Medulloepithelioma | Recurrent Primitive Neuroectodermal Tumor | Embryonal Tumor With Multilayered Rosettes, C19MC-Altered | Recurrent Childhood Central Nervous System... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRefractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditionsUnited States, Canada
-
Giselle ShollerK C Pharmaceuticals Inc.; USWM, LLCAvailableEmbryonal Tumor With Abundant Neuropil and True Rosettes | Medulloblastoma | Neuroblastoma | Medulloepithelioma | Ependymoblastoma | Typical Teratoid Rhabdoid TumorUnited States
-
St. Jude Children's Research HospitalNovartis PharmaceuticalsActive, not recruitingGlioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditionsUnited States
-
Nicklaus Children's Hospital f/k/a Miami Children...TerminatedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Embryonal Tumor With Abundant Neuropil and True Rosettes | Metastatic Malignant Neoplasm to the LeptomeningesUnited States
-
Suzhou Genhouse Bio Co., Ltd.Not yet recruitingPatient With Advanced Solid TumorChina
-
Novartis PharmaceuticalsCompleted
-
Brugmann University HospitalCompletedElderly Patients With a Solid TumorBelgium
-
Novartis PharmaceuticalsCompletedSolid Tumor With p53 Wild Type StatusFrance, Germany, Singapore, Switzerland, United States
-
Children's Oncology GroupRecruitingTeratoma | Choriocarcinoma | Germinoma | Germ Cell Tumor | Yolk Sac Tumor | Embryonal Carcinoma | Mixed Germ Cell Tumor | Late Effects | Pediatric Germ Cell TumorUnited States